
KalVista Pharma (KALV) Stock Forecast & Price Target
KalVista Pharma (KALV) Analyst Ratings
Bulls say
KalVista Pharmaceuticals Inc. is poised for a strong market entry with its FDA-approved product, sebetralstat, which offers a highly effective oral solution for treating acute attacks of hereditary angioedema (HAE), indicating a potential shift in patient treatment paradigms. Insights from allergists and immunologists suggest a favorable reception, with two-thirds of surveyed doctors believing that patients would be more inclined to use an oral medication, supporting a conservative projection of approximately $400 million in worldwide peak sales. The company’s robust clinical data and the anticipated positive reception of sebetralstat ahead of its June 17 PDUFA, coupled with its promising performance in treating adolescents, further establish a strong foundation for future revenue growth and market capture.
Bears say
KalVista Pharmaceuticals Inc. reported a significant net loss of $44.3 million, equating to $0.92 per share for the third quarter of FY3Q25, underscoring ongoing financial challenges as the company is likely to incur losses through sebetralstat’s early launch phase. Furthermore, if sebetralstat does not perform as anticipated, the company’s pipeline lacks sufficient developmental candidates to drive future growth, which poses a substantial risk to its operational continuity and financial stability. Additionally, the inherent regulatory uncertainties surrounding FDA approval and potential market acceptance of its oral therapies, particularly for acute treatments, further exacerbate the risks associated with its business model.
This aggregate rating is based on analysts' research of KalVista Pharma and is not a guaranteed prediction by Public.com or investment advice.
KalVista Pharma (KALV) Analyst Forecast & Price Prediction
Start investing in KalVista Pharma (KALV)
Order type
Buy in
Order amount
Est. shares
0 shares